The CITRELOCK DUO is an exciting addition to Acuitive’s portfolio and is the second in a series of new products that will be launched with a focus on the Sports Medicine market.
New Sports Medicine Fixation Device for Biceps Tenodesis and Tendon Transfer Procedures. (Credit: Acuitive Technologies)
Acuitive Technologies, Inc. (Acuitive) today announced the FDA 510(k) Clearance of CITRELOCK DUO Fixation Device for biceps tenodesis. The new fixation device provides surgeons a differentiated design via a tendon-friendly spiral thread featuring a next-generation resorbable technology, known as CITREGEN®, that has unique molecular and mechanical properties for orthopedic surgical applications.
The CITRELOCK DUO offers surgeons:
Biomimetic material composition to match the native bone inorganic content
A novel soft spiral thread design to avoid tendon laceration
A compressive strength similar to cortical bone and a modulus similar to trabecular bone
Elastomeric properties for improved pull-out strength
A controlled resorption rate to mitigate chronic inflammation
“Our customers are looking for a fixation device with unique mechanical properties that protects the tendon’s integrity during insertion while providing improved fixation within the bone tunnel. Additionally, the CITRELOCK DUO provides more predictable resorption while avoiding the chronic inflammation reported with other biodegradable polymers. With its innovative CITREGEN material technology and unique thread design, the CITRELOCK DUO fills the clinical need surgeons have been seeking,” said Rui Ferreira, VP of Product Development, Acuitive.
The CITRELOCK DUO is an exciting addition to Acuitive’s portfolio and is the second in a series of new products that will be launched with a focus on the Sports Medicine market.
Source: Company Press Release